Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) EBITDA: 2016-2019

Historic EBITDA for Monopar Therapeutics (MNPR) over the last 4 years, with Dec 2019 value amounting to -$4.2 million.

  • Monopar Therapeutics' EBITDA fell 35.39% to -$1.2 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$4.2 million, marking a year-over-year decrease of 38.86%. This contributed to the annual value of -$4.2 million for FY2019, which is 31.05% down from last year.
  • According to the latest figures from FY2019, Monopar Therapeutics' EBITDA is -$4.2 million, which was down 31.05% from -$3.2 million recorded in FY2018.
  • Monopar Therapeutics' EBITDA's 5-year high stood at -$1.2 million during FY2016, with a 5-year trough of -$16.6 million in FY2017.
  • Moreover, its 3-year median value for EBITDA was -$4.2 million (2019), whereas its average is -$8.0 million.
  • In the last 5 years, Monopar Therapeutics' EBITDA plummeted by 1,287.87% in 2017 and then spiked by 80.49% in 2018.
  • Over the past 4 years, Monopar Therapeutics' EBITDA (Yearly) stood at -$1.2 million in 2016, then crashed by 1,287.87% to -$16.6 million in 2017, then skyrocketed by 80.49% to -$3.2 million in 2018, then crashed by 31.05% to -$4.2 million in 2019.